Background We aimed to accurately estimate the frequency of a hexanucleotide repeat expansion in C9orf72 that has been associated with a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by rapidly progressive paralysis and death from respiratory failure, typically within 3 years of symptom onset. The disease is inherited in about 5% of cases, following a clear Mendelian pattern, whereas most cases are classifi ed as sporadic because they seem to arise at random. 1 Substantial progress has been made in understanding the genetic underpinnings of familial ALS. 2 By contrast, the causes of sporadic or idiopathic ALS are far less well understood. Mutations in the known familial ALS genes-SOD1, FUS, and TDP-43-occur only rarely in sporadic cases (each accounting for less than 1·0% of cases); [3] [4] [5] genome-wide association studies have identifi ed few risk loci, and these have proved diffi cult to replicate. 6 Frontotemporal dementia (FTD) is a degenerative disorder of the frontal and anterior temporal lobes, and is a common form of dementia aff ecting individuals younger than 65 years. The syndrome is characterised clinically by initial behavioural disturbances, followed by cognitive decline leading to dementia and death within a median of 7 years from symptom onset. Akin to ALS and other neurodegenerative diseases, a large proportion (~60·0%) of these cases are categorised as sporadic, and the causes of this idiopathic form of disease are largely unknown. 7 A growing consensus suggests that ALS and FTD form part of a continuum of neurological diseases that share a common pathological background, consisting of TAR DNAbinding protein 43 (TDP-43)-positive inclusions within the CNS. 8 We recently reported that a large hexanucleotide repeat expansion located within the non-coding portion of C9orf72 is the cause of chromosome 9-linked ALS and FTD. 9, 10 This genetic lesion accounted for a large proportion (~40·0%) of familial cases of ALS and FTD. The same mutation was present in nearly a quarter of apparently sporadic cases of ALS and FTD in the genetically homogeneous Finnish population, and in 4·1% of sporadic cases of ALS and 3·0% cases of sporadic FTD from the USA. However, these estimates were based on relatively small cohorts drawn from a small number of institutions.
These fi ndings prompted us to aim to estimate the frequency of this C9orf72 hexanucleotide repeat expansion more accurately, in a large cohort of European and US patients with sporadic ALS and sporadic FTD. We also examined the occurrence of this mutation in diverse non-white populations around the world.
Methods

Participants and study design
In this cross-sectional study, we screened 4448 patients diagnosed with ALS and 1425 patients diagnosed with FTD from 17 distinct regions worldwide. The appendix shows ethnic origin and clinical features of the patients. 3860 patients had sporadic ALS, 1022 had sporadic FTD, 588 had familial ALS, and 403 had familial FTD. Data for 401 Finnish patients with ALS, 233 other Europeans with familial ALS, 75 Finnish patients with FTD, 340 Dutch patients with FTD, and 420 English patients with FTD have been published previously. [10] [11] [12] All these cohorts were analysed to provide a comprehensive assessment of the global frequency of the expansion.
Patients with ALS were diagnosed according to the El Escorial criteria, 13 and patients with FTD were diagnosed according to the Lund-Manchester criteria. 14 We classifi ed patients' disease as familial in nature on the basis of a diagnosis of ALS or FTD in any other family member (irrespective of relationship), as reported at the time of sample collection. We based ethnic and racial classifi cation on self-reports from patients at the time of sample collection. Case numbers 15 The remaining cohorts were recruited through medical centres and from repositories in various countries.
We also screened 2585 neurologically healthy control individuals from Australia (213 patients), Finland (478), Germany (309), the Human Gene Diversity Panel (300), mainland Italy (354), Sardinia (87), and the USA (844) for presence of the pathogenic repeat expansion. 1167 of these individuals have been reported elsewhere. 10 None of the control individuals had been diagnosed with ALS, FTD, dementia, or any other neurodegenerative disease. Ethics committees from the respective institutions approved the study, and written informed consent was obtained from all patients and control individuals.
Procedures
We used our previously described 10 repeat-primed PCR assay to screen patients and control individuals for the presence of the chromosome 9p21 GGGGCC hexanucleotide repeat expansion (see appendix for technical details). The assay allows samples to be categorised into those that carry a pathogenic repeat expansion (>30 repeats) and those that carry only wildtype alleles (<20 repeats).
For haplotype analysis, we analysed genome-wide single-nucleotide polymorphism (SNP) data from 262 patients who carried the repeat expansion. We previously reported the identifi cation in the Finnish population of a 42-SNP founder haplotype across the 232 kb block of chromosome 9p21 where the pathogenic hexanucleotide expansion was ultimately established. 16, 17 In this study, we used a custom perl software script to compare unphased sample genotype data with the 42-SNP founder risk haplotype. 16 We estimated mutation ages for all populations separately with the DMLE+ version 2.3 Bayesian linkage disequilibrium gene mapping package. 18 Mutation ages were iterated for 10 000 burn-in iterations and a further 10 000 iterations of the maximum-likelihood model. To obtain generalisable estimates of age of the repeat per population, we used median values of binned estimates passing the α threshold of 0·05 per iteration.
Statistical analysis
We calculated 95% CIs for proportions with the ClopperPearson exact method. We estimated penetrance of the GGGGCC hexanucleotide repeat expansion in relation to the patients' age on the basis of data available for 603 mutant-gene carriers with the Kaplan-Meier method using the survival package within R statistical software (version 2.9.0), but substituting patient age at symptom onset for survival time. 19 We assessed diff erences between groups with the χ² test for discrete variables such as sex, family history, and site of onset. 
Role of the funding source
The sponsors of the study had no role in study design, data collection, analysis, or interpretation, writing of the report, or in the decision to submit the paper for publication. All authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results Table 1 and the appendix show the frequency of the C9orf72 hexanucleotide repeat expansion in patients diagnosed with sporadic ALS and sporadic FTD from diff erent geographical regions. Data for 289 patients with sporadic ALS and 605 with sporadic FTD have been reported elsewhere. [10] [11] [12] The pathogenic expansion was identifi ed in 236 (7·0%) of 3377 white patients from the USA, Europe, the Middle East, and Australia, two (4·1%) of 49 black patients from the USA, and six (8·3%) of 72 Hispanic patients from the USA who were diagnosed with sporadic ALS. The rate of the pathogenic expansion was lower in sporadic FTD: 59 (6·0%) of 981 white patients from Europe carried the mutation. By contrast, the GGGGCC repeat expansion was not present in patients of Native American, Asian, or Pacifi c Islander origin who had sporadic disease (table 1), although this might refl ect the smaller size of the cohorts screened in these populations.
In addition to sporadic cases, we screened 588 familial cases of ALS and 403 familial cases of FTD for the presence of the C9orf72 repeat expansion (table 2, appendix). Of these, 345 patients with familial ALS and 230 with familial FTD have been reported elsewhere. [10] [11] [12] Overall, 221 (37·6%) of 588 patients with familial ALS and 101 (25·1%) of 403 patients with familial FTD carried the genetic lesion, reinforcing our previous fi ndings that this mutation was responsible for an Number of patients 27 300 000 See Online for appendix unparalleled proportion of cases of these diseases. 10 We identifi ed one Japanese individual diag nosed with familial ALS who carried the hexanucleotide repeat expansion. We also showed that one patient with familial FTD from Lund, Sweden, carried the expansion, suggesting that the chromosome 9p21 genetic lesion might be responsible for the geographical cluster of patients with FTD noted in that region. 20 Of 2585 neurologically healthy control samples screened for the C9orf72 repeat expansion, fi ve (0·2%) were carriers: two were previously reported elderly individuals from Finland, 10 and the other three were individuals younger than 40 years from Germany and the USA (appendix).
Within Europe, the highest mutation frequency was noted in the Finnish population (21·1% of patients with sporadic ALS and 18·8% of patients with sporadic FTD). 10 About 6% of patients with sporadic ALS from Germany and England carried the expansion, whereas Italian patients with ALS had a lower rate (4·1%). 7·8% of patients with sporadic ALS from the genetically isolated island population of Sardinia had the mutation and the Dutch population had the lowest detected rate observed in European countries (2·2% of sporadic cases of FTD). White populations from Australia and the USA had an intermediate rate, with about 5·0% of patients with sporadic ALS carrying the pathogenic repeat expansion, perhaps because of the population and immigration histories of these countries.
Haplotype analysis suggested that every patient carrying the pathogenic GGGGCC repeat expansion also shared the Finnish founder risk haplotype, at least in part (fi gure 1). Furthermore, patients with sporadic and familial disease carried the same founder risk haplotype. These fi ndings suggest that the pathogenic hexanucleotide repeat expansion in C9orf72 might have occurred on one occasion in human history and sub sequently disseminated throughout these populations. Analysis of haplotype sharing between these cases estimated the age of C9orf72 repeat expansion to be about 1500 years old (representing a median of 100·5 generations [IQR 57·6-127·6], assuming a generation is 15 years old).
In analysis of age-related penetrance (fi gure 2), the pathogenic expansion was non-penetrant in carriers who were younger than 35 years of age, increasing to 50% penetrance by 58 years, and to almost full penetrance by 80 years. We noted no diff erence between disease penetrance according to familial status, ALS or FTD diagnosis, sex, or age of symptom onset in patients with ALS or FTD (appendix). Table 3 shows clinical details of patients carrying the hexanucleotide repeat expansion. Patients with ALS and the pathogenic repeat expansion were more likely to be female (p=0·0008), have a family history of disease (p<0·0001), and to have bulbar-onset disease (p=0·0011) than were patients who did not carry the expansion. Patients with FTD carrying the repeat expansion were also more likely to have a family history of disease (p<0·0001) and to present with behavioural variant FTD (p<0·0001).
Discussion
Our data show that the C9orf72 hexanucleotide repeat expansion is the most frequent cause of sporadic ALS and sporadic FTD identifi ed thus far, accounting for 
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With expansion (n=465 Data are mean (range; SD) or n (%). *Data not available for age at onset for 19 patients and site of onset for 45 patients. †Data not available for age at onset for 305 patients, sex for 130 patients, and site of onset for 395 patients. ‡Data not available for age at onset for eight patients and site of onset for 36 patients. §Data not available for age at onset for 71 patients, sex for32 patients, and site of onset for 220 patients. about 5·0-7·0% of cases in white Europeans, Americans, and Australians in our large cohort. These frequency rates were slightly higher than were estimates from smaller cohorts obtained at one institution. 9 Before identifi cation of the genetic lesion underlying chromosome 9-linked ALS and FTD, mutations in the SOD1 gene were the most common known genetic cause of sporadic ALS (accounting for 0·7% of cases in a population-based cohort), 3 whereas mutations in the PGRN gene were the most common known cause of sporadic FTD (3·0-4·0% in clinic referral series). 21 The high frequency of the pathogenic expansion in our cohort is consistent with previous genome-wide association studies that identifi ed the association signal on chromosome 9p21 as the only replicable locus in the sporadic form of ALS and FTD. 16, [22] [23] [24] Our fi ndings confi rm the importance of genetics in the pathogenesis of the idiopathic form of these neurodegenerative diseases.
Our haplotype data suggest that the pathogenic GGGGCC hexanucleotide repeat expansion in C9orf72 arose from a one-off mutation event 16, 17 that occurred about 1500 years ago. The geographical distribution of the mutation suggests that the mutation appeared in northern Europe and spread from there. Alternatively, the high frequencies in Finland and other isolated populations could be explained by the history of these communities. Finland and Sardinia are comparatively isolated regions, and have genetically homogeneous populations that originated from a small number of founders. 25 Genetic drift has had a large infl uence on allele frequencies in these populations and could explain the high occurrence of the mutation in these geographical isolates.
Recognition that all patients carrying the C9orf72 repeat expansion share a common ancestor has important implications for the interpretation of global frequency data for this mutation. Although the hexanucleotide repeat expansion is common in white Europeans, it is also present in black and Hispanic populations in the USA and individuals from Israel. This fi nding probably refl ects the scale and nature of past human migration and intermarriage between ethnic groups. Similarly, the relative absence of the pathogenic hexanucleotide repeat in India, Asia, and the Pacifi c Islands might be explained by the greater physical distances of these regions from Europe, and the consequent lack of admixture between populations. Notably, the one Japanese patient who we identifi ed as a carrier of the C9orf72 expansion carried the Finnish risk haplotype, reinforcing the notion that the expansion occurred on one occasion in the past.
The sharing of a common risk haplotype in the C9orf72 region of chromosome 9p21 in patients with sporadic and familial ALS suggests that these apparently sporadic cases are actually cryptically related familial cases. This scenario might have occurred for several reasons, including unfamiliarity with the pedigree on the part of the patient or neurologist or because previous generations might have died at a young age before onset of neurological symptoms. The median age at onset in patients with the expansion was 57 years, and life expectancy in the USA began to exceed this point only in the early 1940s. 26 Furthermore, the incomplete penetrance of the mutation, in which not all individuals carrying the expansion manifest a clinical phenotype, might be a contributing factor in apparently sporadic disease. In deed, we have reported symptom onset in the ninth decade of life in patients carrying the expansion and also encountered two elderly, neurologically healthy indi viduals with the expansion. Thus, the penetrance of this mutation seems to be complete only at a late stage of life, which is an observation of particular relevance for genetic counselling of healthy individuals carrying the expansion. The molecular biological substrate underlying this variability in age at onset is unclear: it might be driven by diff erences in expansion lengths between patients, by age-related methylation across the locus, or by genetic factors elsewhere in the genome.
We compared our results with those of previous studies that reported the frequency of the C9orf72 hexanucleotide repeat expansion in the pathogenesis of ALS and FTD (panel). Data were available from seven studies (appendix). Our study screened one of the largest cohorts of cases of ALS and FTD assessed to date, and also provides an initial report of the frequency of the pathogenic repeat expansion in non-white patients, a detailed examination of the haplotype across the locus, and an initial estimate of age-related disease
Panel: Research in context
Systematic review
We searched Medline up to December, 2011, without language restrictions for relevant publications and selected studies that reported the GGGGCC hexanucleotide repeat expansion in C9orf72 in pathogenesis of amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). On the basis of these criteria, seven studies were identifi ed for further assessment (appendix). The number of patients screened for the pathogenic repeat expansion and the phenotype and ethnic origin reported by these studies are summarised in the appendix.
Interpretation
We report the frequency of the C9orf72 repeat expansion in a large cohort of patients with sporadic ALS and sporadic FTD. We also screened a large number of non-white patients for the expansion, and present frequency data for the mutation in these populations. We confi rmed that the C9orf72 repeat expansion explains a substantial proportion of sporadic ALS (~7·0%) and sporadic FTD (~6·0%) cases in white populations. We also noted that patients with sporadic and familial disease carrying the expansion share a founder risk haplotype, suggesting that these patients have a common ancestor and that the original mutational event that led to the repeat expansion occurred only once in the past. We provide initial estimates of age-related penetrance, showing that 50% of carriers manifest disease by 58 years of age, and that the mutation is fully penetrant by 80 years of age.
penetrance in a large group of individuals carrying the expansion.
Our data have implications for the clinical care of patients diagnosed with ALS and FTD. The clinical standard of care is to off er genetic testing to patients reporting a family history of ALS or FTD, 27 and to reassure patients classifi ed as having sporadic disease that their relatives are not at increased risk of neuro degeneration. On the basis of an analysis of 191 Irish patients with ALS, Byrne and colleagues 28 suggested that genetic testing for the C9orf72 repeat expansion is unnecessary in aff ected individuals without a family history of disease or substantial cognitive impairment. By contrast, we believe that genetic testing is a valuable technique for accurate diagnosis of the two disorders and in the decision-making process for patients and their families. The discrepancy between these two views might stem from diff erences in how sporadic and familial disease were defi ned in the two studies. Accumulation of suffi cient data is an important step towards answering this key question for management of patients. In view of the large number of patients who carry the repeat expansion, investigators and clinicians should at least consider a focused debate on this issue.
Our paper has some limitations. First, the number of patients from some geographical regions was small and the mutational frequencies might change for those ethnic groups as additional patients are screened. Never theless, our data for more than 5000 patients with ALS or FTD provide a reasonable estimation of C9orf72 global frequency. Second, although we have examined the chromosome 9p21 haplotype in a large and diverse cohort of individuals carrying the pathogenic expansion, additional testing of carriers might reveal other haplotypes, thereby indicating that the expansion arose on more than one occasion. Nevertheless, our data suggest that most expansion carriers share a common ancestor. 16, 17 Third, we generated age-related penetrance estimates on the basis of data from retrospective cohorts, which potentially leads to overestimation of penetrance. Additional prospective studies examining family kindreds are necessary to confi rm these estimates. Finally, case classifi cation as familial or sporadic was done on the basis of clinical questioning at sample collection. The level of scrutiny might have varied between centres and countries, but re-collection of this information for existing cohorts was not feasible.
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